Charles Schwab
RXRX icon

Charles Schwab’s Recursion Pharmaceuticals RXRX Stock Holding History

Charles Schwab’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2M Buy
4,138,286
+329,488
+9% +$1.1M ﹤0.01% 1961
2026
Q1 		$11.7M Sell
3,808,798
-185,853
-5% -$718K ﹤0.01% 2029
2025
Q4 		$16.3M Buy
3,994,651
+549,631
+16% +$2.72M ﹤0.01% 1876
2025
Q3 		$16.8M Buy
3,445,020
+855,818
+33% +$4.49M ﹤0.01% 1847
2025
Q2 		$13.1M Buy
2,589,202
+310,801
+14% +$1.53M ﹤0.01% 1886
2025
Q1 		$12.1M Buy
2,278,401
+4,398
+0.2% +$32.1K ﹤0.01% 1863
2024
Q4 		$15.4M Buy
2,274,003
+333,323
+17% +$2.24M ﹤0.01% 1829
2024
Q3 		$12.8M Buy
1,940,680
+288,926
+17% +$2.07M ﹤0.01% 1915
2024
Q2 		$12.4M Buy
1,651,754
+438,742
+36% +$3.83M ﹤0.01% 1934
2024
Q1 		$12.1M Buy
1,213,012
+22,130
+2% +$246K ﹤0.01% 1900
2023
Q4 		$11.7M Buy
1,190,882
+32,916
+3% +$235K ﹤0.01% 1901
2023
Q3 		$8.86M Buy
1,157,966
+157,189
+16% +$1.57M ﹤0.01% 1979
2023
Q2 		$7.48M Buy
1,000,777
+16,838
+2% +$118K ﹤0.01% 2050
2023
Q1 		$6.56M Sell
983,939
-742
-0.1% -$5.89K ﹤0.01% 2075
2022
Q4 		$7.59M Buy
984,681
+80,177
+9% +$786K ﹤0.01% 2003
2022
Q3 		$9.62M Buy
904,504
+476,162
+111% +$4.82M ﹤0.01% 1858
2022
Q2 		$3.49M Buy
428,342
+55,178
+15% +$369K ﹤0.01% 2351
2022
Q1 		$2.67M Sell
373,164
-4,075
-1% -$43.3K ﹤0.01% 2549
2021
Q4 		$6.46M Buy
377,239
+194,467
+106% +$3.66M ﹤0.01% 2224
2021
Q3 		$4.21M Buy
182,772
+17,891
+11% +$507K ﹤0.01% 2456
2021
Q2 		$6.02M Buy
+164,881
New +$4.88M ﹤0.01% 2257

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Charles Schwab's RXRX Position: Q2 2026 in Review

Charles Schwab increased its Recursion Pharmaceuticals (RXRX) stake by 8.7% in Q2 2026, buying an estimated $1.1M and bringing the position to 4,138,286 shares worth $15.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

Charles Schwab first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $16.8M in Q3 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Charles Schwab held 4,138,286 shares of Recursion Pharmaceuticals worth $15.2M as of Q2 2026.
  • Charles Schwab bought 329,488 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.1M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1961 holding.
  • Charles Schwab first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Charles Schwab's Recursion Pharmaceuticals position peaked at $16.8M in Q3 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.